Hepatitis B treatment vaccine on the basis of inactivated, whole recombinant Hansenula polymorpha cells expressing HBsAg
AssigneeHemu Wang
InventorsHemu Wang, Changhua Wang, Jun Yang
Life of this patent
Estimating the term…
Abstract
A hepatitis B treatment vaccine on the basis of inactivated, whole recombinant Hansenula polymorpha cells expressing HBsAg. The vaccine is the HBsAg expressed in recombinant Hansenula polymorpha cells. 108 cells contain 6-10 μg HBsAg as an antigen; the vaccine contains a total of 16-21 HBsAg-specific CTL epitopes; the vaccine uses optimized inactivated, fully recombinant Hansenula polymorpha cells as an adjuvant.
Claims10
A hepatitis B therapeutic vaccine based on inactivated whole recombinant Hansenula polymorpha cells expressing HBsAg, wherein the hepatitis B therapeutic vaccine uses the inactivated whole recombinant Hansenula polymorpha cells as an adjuvant, the intracellular expression level of HBsAg in the recombinant Hansenula polymorpha cells is 6-10 μg HBsAg per 108 cells;
- and each HBsAg has 19 HBsAg-specific CTL epitopes, and the DNA sequence expressed by the recombinant Hansenula polymorpha cell is shown as SEQ ID NO:
- 1.
A recombinant Hansenula polymorpha, wherein the recombinant Hansenula polymorpha comprises the nucleotide sequence of SEQ ID NO:
- 1, and the nucleotide sequence of SEQ ID NO:
- 1 is integrated into the genome of the recombinant Hansenula polymorpha.
Dependencies are inferred from the claim text.